Summary
Cell cycle progression is regulated by the combined action of cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors (CDKi), which are negative cell cycle regulators. p27KIP1 is a CDKi key in cell cycle regulation, whose degradation is required for G1/S transition. In spite of the absence of p27KIP1 expression in proliferating lymphocytes, some aggressive B-cell lymphomas have been reported to show an anomalous p27KIP1 staining. We analysed p27KIP1 expression in a series of Diffuse Large B-cell Lymphoma (DLBCL), correlating it with the proliferative index and clinical outcome, to characterize the implications of this anomalous staining in lymphomagenesis in greater depth. For the above mentioned purposes, an immunohistochemical technique in paraffin-embedded tissues was employed, using commercially available antibodies, in a series of 133 patients with known clinical outcomes. Statistical analysis was performed in order to ascertain which clinical and molecular variables may influence outcome, in terms of disease-free survival (DFS) and overall survival (OS). The relationships between p27KIP1 and MIB-1 (Ki-67) were also tested. An abnormally high expression of p27KIP1 was found in lymphomas of this type. The overall correlation between p27KIP1 and MIB-1 showed there to be no significant relationship between these two parameters, this differing from observations in reactive lymphoid and other tissues. Analysis of the clinical relevance of these findings showed that a high level of p27KIP1 expression in this type of tumour is an adverse prognostic marker, in both univariate and multivariate analysis. These results show that there is abnormal p27KIP1 expression in DLBCL, with adverse clinical significance, suggesting that this anomalous p27KIP1 protein may be rendered non-functional through interaction with other cell cycle regulator proteins.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bani, M. R., Rak, J., Florenes, V. A., Ben-David, Y. & Kerbel, R. S. (1997). Overexpression of p27KIP1 is associated with enhanced survival under three-dimensional growth conditions during melanoma progression. Proc Am Assoc Cancer Res 38: 496
Blain, S. W., Montalvo, E. & Massague, J. (1997). Differential interaction of the cyclin-dependent kinase (CDK) inhibitor p27KIP1 with cyclin A-CDK2 and cyclin D2-CDK4. J Biol Chem 41: 25863–25872.
Catzavelos, C., Bhattacharva, N., Ung, Y., Wilson, J., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. & Slingerland, J. (1997). Decreased levels of the cell cycle inhibitor p27KIP1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227–230.
Chan, F. K. M., Zhang, J., Cheng, L., Shapiro, D. N. & Winoto, A. (1995). Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol Cell Biol 15: 2682–2688.
Cheng, M., Sexl, V., Sherr, C. J. & Rousell, M. F. (1998). Assembly of cyclin D-dependent kinase and titration of p27KIP1 regulated by mitogen-activated protein kinase (MEK1). Proc Natl Acad Sci USA 95: 1092–1096.
Coats, S., Flanagan, W. M., Nourse, J. & Roberts, J. M. (1996). Requirement of p27KIP1 for restriction point control of the fibroblasts cell cycle. Science 2: 877–880.
Cox, D. R. (1972). Regression models and life tables. J R Stat Soc, (B) 34: 187–220.
Croix, B. S., Florenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M. & Kerbel, R. S. (1996). Impact of the cyclin-dependent kinase inhibitor p27KIP1 on resistance of tumor cells to anticancer agents. Nat Med 2: 1204–1210.
El-Deiry, W. S., Tokino, T., Veculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W. & Vogesltein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
Erlanson, M., Portin, C., Linderholm, B., Lindh, J., Roos, G. & Landberg, G. (1998). Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas; prognostic implications. Blood 92: 770–777.
Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M. & Giordano, A. (1997). Prognostic role of the cyclin-dependent kinase inhibitor p27KIP1 in non-small-cell lung cancer. Cancer Res 15: 3381–3385.
Fang, F., Orend, G., Watanabe, N., Hunter, T. & Ruoslathi, E. (1996). Dependence of cyclin E–CDK2 kinase activity on cell anchorage. Science 271: 499–502.
Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L-H, Broudy, V., Perlmutter, Kaushansky, K. & Roberts, J. M. (1996). A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27KIP1-deficient mice. Cell 85: 733–744.
Fredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., Barnes, D. M., Shousha, S., O’Hare, M. J. & Lu, X. (1997). High level expression of p27KIP1 and cylin D1 in some human breast cancer cells: Inverse correlation between the expression of p27KIP1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380–6385.
Gascoyne, R. D., Adomat, S. A., Krajewski, S., Krajewska, M., Horsman, D. E., Tolcher, A. W., O’Reilly, S. E., Hoskins, P., Coldman, A. J., Reed, J. C. & Connors, J. M. (1997). Prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 90: 244–251.
Grogan, T. M., Lippman, S. M., Spier, C. M., Slymen, D. J., Rybski, J. A., Rangel, C. S., Richter, L. C. & Miller, T. P. (1988). Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71: 1157–1160.
Guan, K-L, Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O’Keefe, C. L., Matera, A. G. & Xiong, Y. (1994). Growth suppression by p18, a p16INK4/MTS1 and p14INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939–2952.
Hannon, G. J. & Beach, D. (1994). p15INK4B is a potential effector of TGF-β induced cell cycle arrest. Nature 371: 257–261.
Harper, J. W., Adami, G. Y., Wei, N., Keyomarsi, K. & Elledge, S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent. Cell 75: 805–816.
Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K., Cleary, M. L., Delsol, G., De Wolf-Peeters, C., Falini, B. & Gatter, K. C. (1994). A revised European–American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 84: 1361–1392.
Hengst, L. & Reed, S. I. (1996). Translational control of p27KIP1 accumulation during the cell cycle. Science 271: 1861–1864.
Hermine, O., Haioun, C., Lepage, E., d’Agay, M. F., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J. P., Diebold, J., Reyas, F. & Gaulard P for the Groupe d’Etude des Lymphomes de l’Adulte, (GELA) (1996). Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Blood 87: 265–272.
Hill, M. E., MacLennan, K. A., Cunningham DCVaughan Hudson, B., Burke, M., Clarke, P., Di Stefano, F., Anderson, L., Vaughan Hudson, G., Mason, D., Selby, P. & Linch, D. C. (1996). Prognostic significance of Bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large non-Hodgkin’s lymphoma: a British national lymphoma investigation study. Blood 88: 1046–1051.
Kaplan, E. L. & Meier, P. (1958). Non-parametric estimation for incomplete observations. J Am Stat Assoc 53: 457–481.
Kato, J., Matsuoka, M., Polyak, K., Massague, J. & Sherr, C. J. (1994). Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27KIP1) of cyclin-dependent kinase 4 activation. Cell 79: 487–496.
Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilczynski, S., Lee, Y. Y., Bartran, C. R. & Koeffler, H. P. (1995). Molecular analysis of the cyclin-dependent kinase inhibitor gene p27KIP1 in human malignancies. Cancer Res 55: 2266–2269.
Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., no, M., Khanam, D., Hayday, A. C., Frohman, L. A. & Koff, A. (1996). Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27KIP1. Cell 85: 721–732.
Kramer, M. H. H., Hermans, J., Parker, J., Krol, A. D., Kluin-Nelemans, J. C., Haak, H. L., van Groningen, K., van Krieken, J. H., de Jong, D. & Kluin, P. M. (1996). Clinical significance of bc12 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 14: 2131–2138.
Lee, M. H., Reynisdóttir, I. & Massagué, J. (1995). Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639–649.
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, M. & Pagano, M. (1997). Increased proteasoma-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231–235.
Mantel, C., Luo, Z., Canfield, J., Braun, S., Deng, C. & Broxmeyer, H. E. (1996). Involvement of p21CIP1 and p27KIP in the molecular mechanism of Steel Factor-induced proliferative synergy in vitro and of p21CIP1 in the maintenance of stem/progenitor cells in vivo. Blood 88: 3710–3719.
Mantel, N. (1966). Evaluation of survival and two new rank order statistics arising in its consideration. Cancer Chemother Rep 55: 163–170.
Martin, A. R., Weisenburger, D. D., Chan, W. C., Ruby, E. I., Anderson, J. R., Vose, J. M., Bierman, P. J., Bast, M. A., Daley, D. T. & Armitage, J. O. (1995). Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85: 3671–3678.
Matsuoka, S., Edwars, M., Bai, C., Parker, S., Zhang, P., Baldin, A., Harper, J. W. & Elledge, S. J. (1995). p57KIP2, a structurally distinct member of the Cip1 CDK inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9: 650–662.
Miller, T. P., Grogan, T. M., Dahlberg, S., Spier, C. M., Braziel RM Banks, P. M., Foucar, K., Kjeldsberg, C. R., Levy, N., Nathwani, B. N., Schnitzer, B., Tubbs, R. R., Gaynor, E. R. & Fisher, R. I. (1994). Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: a prospective Southwest Oncology Group Trial. Blood 83: 1460–1466.
Morosetti, R., Kawamata, N., Gombart, A. F., Miller, C. W., Hatta, Y., Hirama, T., Said, J. W., Tomonaga, M. & Koeffler, H. P. (1995). Alterations of the p27KIP1 gene in non-Hodgkin’s lymphomas and adult T-cell leukaemia/lymphoma. Blood 86: 1924–1930.
Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y. & Nakayama, K-I (1996). Mice lacking p27KIP1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707–720.
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M-H, Massague, J., Crabtree, G. R. & Roberts, J. M. (1994). Interleukin-2-mediated elimination of the p27KIP1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570–573.
Pietenpol, J. A., Bohlander, S. K., Sato, Y., Papadopoulos, N., Liu, B., Friedman, C., Trask, B. J., Roberts, J. M., Kinzler, K. W., Rowly, J. D. & Vogelstein, B. (1995). Aassignment of the human p27KIP1 gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206–1210.
Piris, M. A., Pezella, F., Martinez-Montero, J. C., Orradre, J. L., Villuendas, R., Sanchez-Beato, M., Cuena, R., Cruz, M. A., Martinez, B., Garrido, M. C., Gatter, K., Aiello, A., Delia, D., Giardini, R. & Rilke, F. (1994). p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69: 337–341.
Polyak, K., Lee, M-H, Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P. & Massague, J. (1994). Cloning of p27KIP1, a cylin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59–66.
Porter, P., Malone, K., Heagerty, P., Alexander, G., Gatti, L., Firpo, E., Daling, J. & Roberts, J. (1997). Expression of cell-cycle regulators p27KIP1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222–225.
Quintanilla-Martinez, L., Thieblemont, C., Fend, F., Kumar, S., Pinyol, M., Campo, E., Jaffe, E. & Raffeld, M. (1998). Mantle cell lymphomas lack expression of p27KIP1 a cyclin-dependent kinase inhibitor. Am. J Pathol 153: 175–182.
Reynisdottir, I. & Massague, J. (1997). The subcellular locations of p15INK4b and p27KIP1 co-ordinate their inhibitory interactions with CDK4 and CDK2. Genes Dev 11: 492–503.
Sánchez, E., Chacon, I., Plaza, M. M., Muñoz, E., Cruz, M. A., Martinez, B., Lopez, L., Martinez-Montero, J. C., Orrader, J. L., Saez, A. I., Garcia, J. F. & Piris, M. A. (1998). Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell cycle regulator proteins. J Clin Oncol 16: 1931–1939.
Sánchez-Beato, M., Sáez, A. I., Martínez-Montero, J. C., Mateo, M. S., Sánchez-Verde, L., Villuendas, R., Troncone, G. & Piris, M. A. (1997). Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 151: 151–160.
Serrano, M., Hannon, G. J. & Beach, D. (1993). A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707.
Sgambato, A., Zhang, Y., Arber, N., Hibshoosh, H., Doki, Y., Ciaparrone, M., Santella, R. M., Cittadini, A. & Weinstein, I. B. (1997). Deregulated expression of p27KIP1 in Human Breast Cancers. Clinical Cancer Res 3: 1879–1887.
Shiohara, M., El-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B. & Koeffler, H. P. (1994). Absence of Waf1 mutations in a variety of human malignancies. Blood 84: 3781–3784.
Slymen, D. J., Miller, T. P., Lippman, S. M., Spier, C. M., Kerrigan, D. P., Rybski, J. A., Rangel, C. S., Richter, L. C. & Grogan, T. M. (1990). Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 8: 986–993.
Soos, T. J., Kiyokawa, H., Yan, J. S., Rubin, M. S., Giordano, A., DeBlasio, A., Bottega, S., Wong, B., Mendelsohn, J. & Koff, A. (1996). Formation of p27–CDK complexes during the human mitotic cell cycle. Cell Growth Differ 7: 135–146.
The International Non-Hodgkin’s Lymphoma Prognostic Project (1993). A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–994.
Toyoshima, H. & Hunter, T. (1994). p27KIP1, a novel inhibitor of G1 cyclin–CDK protein kinase activity, is related to p21. Cell 78: 67–74.
Vrhorac, R., Delmer, A., Tang, R., Marie, J. P., Zittoun, R. & Ajchenbaum-Cymbalista, F. (1998). Prognostic significance of the cell cycle inhibitor p27KIP1 in chronic B-cell lymphocytic leukemia. Blood 91: 4694–4700.
Wang, X., Gorospe, M., Huang, Y. & Holbrook, N. J. (1997). p27KIP1 overexpression causes apoptoic death of mammalian cells. Oncogene 15: 2991–29978.
Watanabe, H., Fukuchi, K., Takagi, Y., Tomoyasu, S., Tsuruoka, N. & Gomi, K. (1995). Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim Biophys Acta 1263: 275–278.
Yamanaka, N., Harabuchi, Y. & Kataura, A. (1992). The prognostic value of Ki-67 antigen in non-Hodgkin’s lymphoma of Waldeyer ring and the nasal cavity. Cancer 70: 2342–2349.
Yatabe, Y., Masuda, A., Koshikawa, T., Nakamura, S., Kuroishi, T., Osada, H., Takahashi, T., Mitsudomi, T. & Takahashi, T. (1998). P27KIP1 in human lung cancers: differential changes in small-cell and non-small-cell carcinomas. Cancer Res 58: 1042–1047.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sáez, A., Sánchez, E., Sánchez-Beato, M. et al. p27KIP1 is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome. Br J Cancer 80, 1427–1434 (1999). https://doi.org/10.1038/sj.bjc.6690539
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690539
Keywords
This article is cited by
-
Prognostic implication of p27 expression in primary central nervous system lymphoma
Brain Tumor Pathology (2006)
-
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma
Modern Pathology (2005)
-
Kip moving
Nature (2004)
-
Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors?
Nature Reviews Cancer (2004)
-
Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia
Leukemia (2002)